Educational poster presented at ISPOR 20th Annual European Congress, November 2017.
Most Recent Articles

A Comparison Of Individual Patient Data (IPD) Regression Techniques In Adjusting For Cross-Trial Differences...

A Foot In The Door Or One Foot In The Grave? The Role Of Real World Evidence In Cancer Drugs Fund Re-Appraisals

Squaring The Circle? Using Real World Data From Early Access Programs To Inform Pricing And Reimbursement Decision Making

ICER Reports - 4 Years of Cost/QALY Drug Evaluations in the USA...What Does the Future Hold?

Mission Possible? Demonstrating Robust Cost-Effectiveness Without Any Comparative Phase III Data

Is Eunethta Enough? The Remaining Challenges in Navigating the Early European Regulatory and HTA Advice

FDA Orphan Exploitation? Are Pharma's Approaches to Orphan Oncology Drug Approvals Fuelling A Push for Reform by the FDA?

The Future of UK Drug Pricing: The 2014 PPRS - An Interim Review